Cardiosonic
Ultrasonic Energy Solution for Resistant Hypertension
Company Overview
Snapshot
Founded in October 2009, Cardiosonic operated with 11–50 employees, developing medical devices. The company raised $8.6 million across two funding rounds, with Shmuel Almagor participating in one round. In April 2014, Cardiosonic received CE Mark approval for its TIVUS Ablative Catheter Device.
Business overview
Cardiosonic specializes in developing solutions for transluminal, high-intensity ultrasound ablation within the Health Tech & Life Sciences sector. Its core product, the TIVUS high-intensity, directional ultrasound catheter system, is designed for therapeutic renal sympathetic denervation by ultrasound ablation for resistant hypertension. This system enables remote, localized, controlled, and repeatable thermal modulation of the renal vessel wall tissue. The company serves the healthcare industry, particularly providers, with its medical devices and treatments, operating in markets such as Europe and the United States.
Strategic signal
In April 2014, Cardiosonic received CE Mark approval for its TIVUS Ablative Catheter Device. This regulatory milestone was a critical validation for the company's core technology, signaling its readiness for commercialization and market entry in Europe. For investors, this indicated significant progress in product development and a clear path toward generating revenue from its innovative ultrasound ablation system.
Log in to access full profile ›Company Intelligence Q&A
- What is Cardiosonic's primary focus?
- Cardiosonic develops solutions for transluminal, high-intensity ultrasound ablation, with a primary focus on treating resistant hypertension using its TIVUS catheter system.
- When was Cardiosonic founded?
- Cardiosonic was founded in October 2009.
- What is the TIVUS system?
- The TIVUS system is Cardiosonic's flagship product, consisting of a catheter and control console that uses high-intensity, directional ultrasound to ablate renal nerves for therapeutic renal sympathetic denervation.
- What significant regulatory approval did Cardiosonic receive?
- In April 2014, Cardiosonic received CE Mark approval for its TIVUS Ablative Catheter Device, enabling its use in European markets.
- What is the operational status of Cardiosonic?
- Cardiosonic is currently non-active, having ceased to operate in July 2019.